Evommune, Inc.
EVMN
$18.87
-$0.02-0.11%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -57.14% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -57.14% | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -57.14% | ||
| SG&A Expenses | 14.28% | 7.88% | 30.74% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 41.24% | -18.72% | 67.68% | ||
| Operating Income | 19.31% | 18.72% | -300.43% | ||
| Income Before Tax | 21.62% | 50.46% | -422.88% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 21.62% | 50.46% | -422.88% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 21.62% | 50.46% | -422.88% | ||
| EBIT | 19.31% | 18.72% | -300.43% | ||
| EBITDA | 19.58% | 19.11% | -320.76% | ||
| EPS Basic | 22.85% | 51.33% | -400.85% | ||
| Normalized Basic EPS | 22.85% | 51.33% | -400.83% | ||
| EPS Diluted | 22.85% | 51.33% | -400.85% | ||
| Normalized Diluted EPS | 22.85% | 51.33% | -400.83% | ||
| Average Basic Shares Outstanding | 1.59% | 1.78% | 4.40% | ||
| Average Diluted Shares Outstanding | 1.59% | 1.78% | 4.40% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||